Fusobacterium nucleatum-triggered purine metabolic reprogramming drives tumorigenesis in head and neck carcinoma

被引:5
|
作者
Li, Feiran [1 ]
Huang, Huiying [1 ]
Xu, Jing [2 ]
Tao, Lei [1 ]
Zhou, Liang [1 ]
Hsueh, Chiyao [1 ]
Gong, Hongli [1 ]
Zhang, Ming [1 ]
机构
[1] Fudan Univ, Eye & ENT Hosp, Dept Otorhinolaryngol, 83 Fen Yang Rd, Shanghai, Peoples R China
[2] Fudan Univ, Eye & ENT Hosp, Dept Nursing, 83 Fen Yang Rd, Shanghai, Peoples R China
基金
上海市自然科学基金; 中国国家自然科学基金;
关键词
Head and neck carcinoma; Fusobacterium nucleatum; Metabolic reprogramming; Purine metabolic pathway; Prognosis; URIC-ACID; CANCER; RISK;
D O I
10.1007/s12672-023-00727-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundFusobacterium nucleatum (F. nucleatum) is a vital pro-oncogenic bacterium. Our previous study revealed that a high abundance of F. nucleatum in head and neck squamous cell carcinoma (HNSCC) is correlated with poor patient prognosis. However, the impact of F. nucleatum on metabolic reprogramming and tumor progression in HNSCC awaits more exploration.MethodsLiquid chromatography-mass spectrometry (LC-MS) was applied to analyze the altered metabolites in a head and neck carcinoma cell line (AMC-HN-8) after coculture with F. nucleatum for 24 hrs and 48 hrs. Both univariate and multivariate analyses were used to screen for differential metabolites. Kyoto Encyclopedia of Genes and Genomes (KEGG) metabolic pathway enrichment analysis was further used to explore the metabolic changes.ResultsWe observed a significantly altered metabolic profile in AMC-HN-8 cells over time after coculture with F. nucleatum. Among the several enriched pathways, the purine metabolic pathway was the most significantly enriched (P = 0.0005), with downregulation of purine degradation. Furthermore, uric acid, the end product of purine metabolism, significantly reversed F. nucleatum-triggered tumor progression and altered the intracellular reactive oxygen species (ROS) level. Moreover, the negative correlation between the serum uric acid level and the abundance of F. nucleatum was verified in 113 HNSCC patients (P = 0.0412, R = - 0.1924).ConclusionsOur study revealed obviously aberrant purine metabolism driven by F. nucleatum in HNSCC, which was closely related to tumor progression and patient prognosis. These findings indicate the possibility of targeting F. nucleatum-induced purine metabolism reprogramming in the future treatment of HNSCC.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Gankyrin drives metabolic reprogramming to promote tumorigenesis, metastasis and drug resistance through activating β-catenin/c-Myc signaling in human hepatocellular carcinoma
    Liu, Ruiqi
    Li, Yuejin
    Tian, Lantian
    Shi, Huawen
    Wang, Jiabei
    Liang, Yingjian
    Sun, Boshi
    Wang, Shuangjia
    Zhou, Meng
    Wu, Li
    Nie, Jianhua
    Lin, Binlin
    Tang, Shuli
    Zhang, Yanqiao
    Wang, Guangyu
    Zhang, Chunhui
    Han, Jiguang
    Xu, Benjie
    Liu, Lianxin
    Gong, Kunmei
    Zheng, Tongsen
    CANCER LETTERS, 2019, 443 : 34 - 46
  • [22] Metabolic profiling analysis of head and neck squamous cell carcinoma
    Ohashi, Toshimitsu
    Terazawa, Kosuke
    Shibata, Hirofumi
    Inoue, Norimitsu
    Ogawa, Takenori
    ORAL DISEASES, 2024, 30 (02) : 342 - 352
  • [23] Stress-triggered atavistic reprogramming (STAR) addiction: driving force behind head and neck cancer?
    Masuda, Muneyuki
    Wakasaki, Takahiro
    Toh, Satoshi
    AMERICAN JOURNAL OF CANCER RESEARCH, 2016, 6 (06): : 1149 - 1166
  • [24] Identification of a metabolic reprogramming-related signature associated with prognosis and immune microenvironment of head and neck squamous cell carcinoma by in silico analysis
    Qiang, Weijie
    Dai, Yifei
    Xing, Xiaoyan
    Sun, Xiaobo
    CANCER MEDICINE, 2022, 11 (16): : 3168 - 3181
  • [25] Glutamic acid and glutaminolysis mark aggressive tumorigenesis in head and neck squamous cell carcinoma
    Banda, Adam D.
    Cortes, Mercedes Bermudez
    Kamarajan, Pachiyappan
    Rajendiran, Thekkenlnaycke
    Chinnaiyan, Arul M.
    Kapila, Yvonne L.
    CANCER RESEARCH, 2015, 75
  • [26] Cancer stem cells: Mediators of tumorigenesis and metastasis in head and neck squamous cell carcinoma
    Chinn, Steven B.
    Darr, Owen A.
    Owen, John H.
    Bellile, Emily
    McHugh, Jonathan B.
    Spector, Matthew E.
    Papagerakis, Silvana M.
    Chepeha, Douglas B.
    Bradford, Carol R.
    Carey, Thomas E.
    Prince, Mark E. P.
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2015, 37 (03): : 317 - 326
  • [27] The chemotherapeutic-derived surviving cells acquire the metabolic reprogramming in head and neck squamous cancer
    Jie, Grace Hii Hui
    Chang, Wen-chang
    Chen, Ben-Kuen
    BRITISH JOURNAL OF PHARMACOLOGY, 2023, 180 : 282 - 282
  • [28] Statin-induced metabolic reprogramming in head and neck cancer: a biomarker for targeting monocarboxylate transporters
    Mehibel, Manal
    Ortiz-Martinez, Fernando
    Voelxen, Nadine
    Boyers, Amy
    Chadwick, Amy
    Telfer, Brian A.
    Mueller-Klieser, Wolfgang
    West, Catharine M.
    Critchlow, Susan E.
    Williams, Kaye J.
    Stratford, Ian J.
    SCIENTIFIC REPORTS, 2018, 8
  • [29] Fusobacterium is toxic for head and neck squamous cell carcinoma and its presence may determine a better prognosis
    Chander, Anjali
    Iacovacci, Jacopo
    Pellon, Aize
    Kataria, Rhadika
    Grigoriadis, Anita
    Maher, John
    Sears, Cynthia
    Bachrach, Gilad
    Urbano, Teresa Guerrero
    Lei, Mary
    Petkar, Imran
    Kong, Anthony
    Ng, Tony
    Orlandi, Ester
    Iacovelli, Nicola Alessandro
    De Cecco, Loris
    Serafini, Mara Serena
    Moyes, David
    Rancati, Tiziana
    Ferreira, Miguel Reis
    CANCER COMMUNICATIONS, 2024, 44 (08) : 879 - 883
  • [30] Statin-induced metabolic reprogramming in head and neck cancer: a biomarker for targeting monocarboxylate transporters
    Manal Mehibel
    Fernando Ortiz-Martinez
    Nadine Voelxen
    Amy Boyers
    Amy Chadwick
    Brian A. Telfer
    Wolfgang Mueller-Klieser
    Catharine M. West
    Susan E. Critchlow
    Kaye J. Williams
    Ian J. Stratford
    Scientific Reports, 8